Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo

Clinical Cancer Research

Volumn 20, Issue 11, 2014, Pages 2922-2932

  Ottewell, Penelope D ^a   Wang, Ning ^b   Brown, Hannah K ^a   Reeves, Kimberly J ^b   Fowles, C Anne ^b   Croucher, Peter I ^c   Eaton, Colby L ^b   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BALB/C NUDE MOUSE; BONE MASS; BONE METASTASIS; BONE TISSUE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MICRO-COMPUTED TOMOGRAPHY; MICROSCOPY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SHAM PROCEDURE; ANIMAL; BAGG ALBINO MOUSE; BONE; BONE TUMOR; BREAST TUMOR; CONFOCAL MICROSCOPY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; OSTEOCLAST; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLULAR MICROENVIRONMENT; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; OSTEOCLASTS; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; REAL-TIME POLYMERASE CHAIN REACTION; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901785862     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1246     Document Type: Article

References (29)

1. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-405.
2. Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - final analysis. Cancer Res 2011;71(24 Suppl):S2-3.
3. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12:631-41.
4. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle 2006:16:1744-50. (Pubitemid 44435316)
5. Aguirre-Ghiso JA. Models, mechanisms, and evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-846. (Pubitemid 350006258)
6. Weilbaecher KN, Guise TA, McCauley L. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.
7. Shiosawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011;121:1298-312.
8. van der Pluijm G, Que I, Sijmons B, Buijs JT, Löwik CW, Wetterwald A, et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005;65:7682-90. (Pubitemid 41297242)
9. Brown HK, Holen I. Antitumour effects of bisphosphonates- what have we learned from in vivo models? Current Cancer Drug Targets 2009;9:807-23.
10. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78.
11. Cole AA, Walters LM. Tartrate-resistant acid phosphatase in bone and cartilage following decalcification and cold-embedding in plastic. J Histochem Cytochem 1987;35:203-6. (Pubitemid 17228168)
12. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
13. Steinman EA, Brufsky AM, Oesterreich S. Zoledronic acid effectiveness against breast cancer metastases-a role for oestrogen in the microenvironment? Breast Cancer Res 2012;14:213.
14. Kollet O, Dar A, Lapidot T. The multiple roles of osteoclasts in host defence: bone remodelling and hematopoietic stem cell mobilisation. Annu Rev Immunol 2007;25:51-69. (Pubitemid 46697902)
15. Renstrom J, Kroger M, Peschel C, Oostendorp RAJ. How the niche regulates hematopoietic stemcells. Chem Biol Interact 2010;184:7-15.
16. Ellis SL, Grassinger J, Jones A, Borg J, Camenisch T, Haylock D, et al. The relationship between bone, hemopoietic stem cells, and vasculature. Blood 2011;11:1516-24.
17. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, et al. Osteoclasts degrade endosteal components and promote mobilisation of hematopoietic progenitor cells. Nat Med 2006;12:657-64. (Pubitemid 43865234)
18. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010;46:1181-8.
19. Lee SK, Kadono Y, Okada F, Jacquin C, Koczon-Jaremko B, Gronowicz G, et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy.J Bone Miner Res 2006;21:1704-12. (Pubitemid 46141225)
20. Orlíc I, Borovecki F, Simić P, Vukicević S. Gene expression profiling in bone tissue of osteoporotic mice. Arh Hig Rada Toksikol 2007;58:3-11. (Pubitemid 46513127)
21. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76. (Pubitemid 28180851)
22. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19. (Pubitemid 27199902)
23. Van der Horst G, van der Werf SM, Farih-Sips H, van Bezooijen RL, Löwik CW, Karperien M. Downregulation of Wnt Signalling by increased expression of Dkckkopf-1 and -2 is a prerequisite for late stage osteoblast differentiation of KS483 cells. J Bone Mineral Res 2005;20:1867-77. (Pubitemid 41361889)
24. Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soli to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 2006;25:35-43. (Pubitemid 43723980)
25. Aicher A, Kollet O, Heeschen C, Liebner S, Urbich C, Ihling C, et al. the Wnta antagonist Dickkopf-1 mobilises vasculogenic progenitor cells via activation of the bone marrow enodstal stem cell niche. Circ Res 2008;103:796-803.
26. Driessen RL, Johnston HM, Nilsson SK. Membrane bound stem cell factor is a key regulator in the initial lodgement of stem cells within the endosteal marrow region. Exp Hematol 2003;31:1284-91. (Pubitemid 37510034)
27. Kumar S, Ponnazhagan S. Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect. Bone 2012;50:1012-8.
28. Lu C, Li XY, Hu Y, Rowe RG, Weiss SJ. MT1-MMP controls human mesenchymal stem cell trafficking and differentiation. Blood 2010;14:221-229.
29. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009;8:2821-32.